{
  "docId": "019de511-70b9-744d-9fdd-cb0d25e1c298",
  "docSlug": "65af9093c9ec9ca745928fa125179681",
  "documentTitle": "Avantor | Investor Day Presentation Deck | 89 slides",
  "authorId": "avantor",
  "authorName": "Avantor",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 89,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a matrix structure to align market segments (Biologics, Viral Vector, Bioengineered) with trends and company capabilities.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de511-70b9-744d-9fdd-cb0d25e1c298/31",
  "deckHref": "/decks/019de511-70b9-744d-9fdd-cb0d25e1c298",
  "deckJsonHref": "/decks/019de511-70b9-744d-9fdd-cb0d25e1c298.json",
  "deckAnchorHref": "/decks/019de511-70b9-744d-9fdd-cb0d25e1c298#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.33,
        "x": 0.24,
        "y": 0.65
      },
      "kind": "list",
      "text": "COVID vaccines accelerated platform; Pipeline of mRNA vaccines and therapies; First RNA drug approval",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d81be09-70fd-4260-9877-e00a780d2d11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "metric",
      "text": "~10% of Avantor's Bioproduction revenue",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93b7138e-919a-40be-b516-c25f72cba4c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.6,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "NOVEL CHEMICALS FOR SYNTHETIC BIOLOGY; CUSTOM FORMULATION REAGENTS AND EXCIPIENTS; NEW SINGLE-USE FLUID PATHS WITH SPECIALTY MATERIALS",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10d6e51a-780e-4a5b-a00a-28b48b6ccbf6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.96,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "table",
      "text": "Matrix comparing Biologics, Viral Vector, and Bioengineered (mRNA) segments against market trends and Avantor relevance.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23593b69-001d-4824-b9e5-271ac56059be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Recent market evolutions play to Avantor's strengths",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12b4d7cc-c2b4-499b-9857-b88dc06d6f36",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "NxN matrix",
      "slug": "matrix-nxn",
      "agent": null,
      "layer": "slide",
      "matchId": "52779416-b96f-4bca-9575-7589d27e1fd7",
      "evidence": "Matrix comparing Biologics, Viral Vector, and Bioengineered (mRNA) segments against market trends and Avantor relevance.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "eed521fe-220c-4cd6-baf3-d26160012c80",
      "evidence": "The slide uses a structured table to compare market trends against company relevance.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 89,
      "from": 17,
      "beatId": "2aa3ce3e-d4bb-4cda-b13e-25db1a3054af",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "Growth prospects and financial highlights",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 21,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "44a7c149-2da8-4925-9541-064336919963",
      "evidence": "Case study and supporting data",
      "position": 0,
      "objective": "Show how Avantor's offering supports Biopharma R&D activities",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.7,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}